Glimelius I, et al. - Given a poor prognosis for mantle cell lymphoma (MCL), researchers examined how comorbidities influence survival and causes of death. Among 1,385 MCL patients (1,009 males, 376 females) diagnosed in 2000–2014 (median age 71 years, range 22–96), 44% had any comorbidity [Charlson comorbidity index (CCI) 1+] and 28% severe comorbidity (CCI 2+). Death was reported for 633 (46%) over a median follow-up of 3·7 years (range 0–16), the majority (76%) from lymphoma. They observed an independent association of severe comorbidity with higher all-cause and lymphoma-specific mortality, particularly among patients with connective tissue, renal and psychiatric diseases, and dementia. Non-lymphoma deaths represented a larger proportion of all deaths among females vs males with any comorbidity. In general, patients with severe comorbidity should also be offered more efficient lymphoma treatments. However, females with any comorbidity still exhibit a substantial likelihood of non-lymphoma death, perhaps favoring a more liberal use of a “wait and watch” approach.